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Background: Current treatment modalities for chronic leg ulcers are time consuming, expensive, and only moderately
successful. Recent data suggest that creating a subatmospheric pressure by vacuum-assisted closure (V.A.C., KCI
Concepts, San Antonio, Texas) therapy supports the wound healing process.
Methods: The efficacy of vacuum-assisted closure in the treatment of chronic leg ulcers was prospectively studied in a
randomized controlled trial in which 60 hospitalized patients with chronic leg ulcers were randomly assigned to either
treatment by V.A.C. or therapy with conventional wound care techniques. The primary outcome measure was the time to
complete healing (days). Statistical analysis was performed on the intention-to-treat basis.
Results: The median time to complete healing was 29 days (95% confidence interval [CI], 25.5 to 32.5) in the V.A.C.
group compared with 45 days (95% CI, 36.2 to 53.8) in the control group (P .0001). Further, wound bed preparation
during V.A.C. therapy was also significantly shorter at 7 days (95% CI 5.7 to 8.3) than during conventional wound care
at 17 days (95% CI, 10 to 24, P  .005). The costs of conventional wound care were higher than those of V.A.C. Both
groups showed a significant increase in quality of life at the end of therapy and a significant decrease in pain scores at the
end of follow-up.
Conclusions: V.A.C. therapy should be considered as the treatment of choice for chronic leg ulcers owing to its significant
advantages in the time to complete healing and wound bed preparation time compared with conventional wound care.
Particularly during the preparation stage, V.A.C. therapy appears to be superior to conventional wound care techniques.
(J Vasc Surg 2006;44:1029-38.)Chronic leg ulcers (CLUs) affect approximately 1% of
the adult population in developed countries.1 The preva-
lence increases with age and is estimated to be 4% to 5% in
the population aged 80 years.1,2 The course and progno-
sis of patients with leg ulcers differs according to the
underlying pathogenesis, which is venous disease in up to
80%.2
Several treatment modalities and protocols have been
reported to date, all of them mainly focusing on ambulatory
treatment of venous ulcers.2-4 The cornerstones of these
regimens are compression therapy and resolution of the
cause.2-5 It is broadly accepted now that ulcers should be
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doi:10.1016/j.jvs.2006.07.030débrided of necrotic and fibrous tissue to allow formation
of granulation tissue, adequate epithelialization, and to
decrease the chance of infection.2-4,6 Apart from both
surgical or chemical débridement, there is not much evi-
dence for the use of special dressings underneath the com-
pression bandages.2-4,7-10
By following the currently available protocols, about
50% of ulcers will heal 4 months, about 20% do not heal
2 years, and about 8% do not even heal after 5 years.11,12
Furthermore, various studies reported a recurrence rate
after wound healing with nonoperative techniques of up to
57% after 1 year.13 Owing to these poor healing results,
many patients will be admitted to the hospital for inpatient
treatment.
Although the use of suction on wounds has been
known since the late 1950s, it was not until 1993 that
Fleischmann introduced vacuum sealing for soft-tissue
damage in open fractures.14,15 In 1995, Kinetic Concepts,
Inc, San Antonio, Texas introduced into the US market
a commercial system, V.A.C., for promoting vacuum-
assisted closure. The V.A.C. system exerts a controlled, local
subatmospheric pressure in the wound.16
Owing to our own promising retrospective preliminary
data and the relative paucity of prospective randomized
controlled trials, we started a randomized controlled trial to
study the efficacy of V.A.C. in wound healing compared
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recalcitrant CLU as defined in the inclusion criteria. We
also evaluated the effect of V.A.C. therapy on recurrence
rate, quality of life (QOL), pain, comfort, and costs of
treatment.17-19
PATIENTS AND METHODS
Patients. The study was conducted in the Depart-
ments of Dermatology at the University Hospital Maas-
tricht and the Atrium Medical Centre Heerlen, The Neth-
erlands. All patients hospitalized with chronic venous,
combined venous and arterial, or microangiopathic (arte-
riolosclerotic) leg ulcers of 6 months’ duration were
eligible for entry in the study after surgical treatment op-
tions had been exhausted and extensive ambulatory treat-
ment (6 months) in an outpatient clinic according to the
Scottish Intercollegiate Guideline Network (SIGN) had
failed.20
Duplex ultrasound scans of the deep and superficial
venous system, an arterial work-up consisting of Doppler
ultrasound scans, ankle-brachial pressure index (ABI), and
transcutaneous oxygen pressure, as well as bacterial cultures
were performed in all patients. In those with no apparent
venous or macroangiopathic arterial insufficiency but with
decreased transcutaneous oxygen pressure, biopsy speci-
mens were taken to demonstrate microangiopathic (ie,
arteriolosclerotic) changes. On the basis of these findings,
patients were divided into groups: (1) those with chronic
venous insufficiency of the deep or superficial system with-
out an arterial incompetence, (2) those with combined
arterial and venous insufficiency of the deep or superficial
system (ABI, 0.60 to 0.85), or (3) arteriolosclerotic (Mar-
torell’s ulcer, biopsy proven) leg ulcers.
Before inclusion in the study, underlying venous and
arterial insufficiency was dealt with, and patients underwent
ambulatory conservative local treatment for at least 6 months.
This consisted of ambulatory débridement whenever neces-
sary, daily or weekly (whenever necessary) cleansing with tap
water, and nonadherent wound dressings creating a con-
trolled moist wound environment (SIGN guidelines). Be-
cause no wound infections were observed, no topical or sys-
temic antibiotics were used.
Patients with venous or combined venous/arterial leg
ulcers were treated with multilayer, short, stretch bandages.
If the ulcer did not reduce in size after 6 months of
ambulatory treatment, patients were hospitalized to add
bed rest and skin grafting to their treatment and became
eligible for entry in the study.
Patients meeting one of the exclusion criteria—ulcer
chronicity6 months duration, age85 years old, the use
of immune suppression, allergy to wound products, malig-
nant or vasculitis origin, or ABI 0.60—were excluded
from the study. In patients presenting with multiple ulcer-
ations, the clinically most severe CLU, according to the
staging system described by Falanga,21 was included in the
study.
Every patient was provided with trial information
sheets and written informed consent was obtained. Fullethics approval from the respective local medical ethical
committees was obtained, and the study was performed in
accordance with guidelines set forth by the Declaration of
Helsinki.22
Procedures. Hospitalized CLU patients were ran-
domly assigned to the V.A.C. group or to the control group
(standard wound care) by a computer program using ran-
dom permuted blocks of eight. Randomization was carried
out within three strata, one for each ulcer type: venous,
combined venous/arterial, and arteriolosclerotic ulcers.
Treatment allocation occurred through telephone calls to
the coordinating center. In both study groups and both
study centers, an initial necrosectomy was performed by
sharp débridement under local anesthesia until pinpoint
bleeding appeared.6
In patients assigned to treatment with V.A.C., polyure-
thane ether foam was applied to the wound during the
preparation stage. This foam was appropriately trimmed to
fit each individual wound. A noncollapsible drainage tube
embedded in the foam was connected to the V.A.C. pump;
thereafter, an airtight adhesive drape was applied on top of the
foam, and a permanent negative pressure of 125 mm Hg was
exerted. The tube drained the wound secretion into a collec-
tion canister. In this way, a previously open wound was
temporarily converted into a controlled, closed, and moist
wound. A wound was considered to be prepared when
granulation tissue covered 100% of the surface and wound
secretion was minimal.21
Transplantation of full-thickness punch skin grafts was
then performed.23 This autologous grafting, in which
4-mm superficial pieces of skin are normally taken from the
thigh, was performed under local anaesthetic (Xylocaine
1%, AstraZeneca, Wilmington, Del). In conjunction with a
punch graft, the skin is picked up using a rounded biopsy
knife (Biopsy punch, Kai Medical Europe, Solingen, Ger-
many) and cut off. The pieces of skin are placed on the
ulcer, spaced 5-mm apart, and are covered with a nonad-
hesive dressing, such as polyvinylalcohol foam. After 4 days
of continuous subatmospheric pressure, once all skin grafts
attached well, standard wound care was continued using a
nonadhesive dressing (Atrauman; Hartmann, Nijmegen,
The Netherlands) and a multiple-layer compression ban-
dage (Rosidal K; Lohmann & Rauscher, Rengsdorf, Ger-
many), when possible, until complete healing.
Patients assigned to standard wound care received daily
local wound care according to the SIGN guideline and
compression therapy (especially patients with venous or
combined venous/arterial ulcers) until complete healing.20
Compression therapy consisted of double-layered, short,
stretch bandages (Rosidal K,) applied from the toe to below
the knee, creating a submalleolar pressure of 25 to 35 mm
Hg. Two basic types of commercially available wound
dressings were used in this study, including hydrogels (Nu-
gel, Johnson & Johnson, Amersfoort, The Netherlands)
and alginates (Sorbalgon, Hartmann, Paul Hartmann B.V.,
Nijmegen, The Netherlands). The choice of dressing
mostly depended on the wound bed and the amount of
exudate.2-4,7
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wound secretion was seen, these patients also received
punch skin-graft transplantation covered with a nonadhe-
sive dressing (Atrauman) and compression therapy. The
inner dressing was not be changed for 4 days.7,21 Once all
skin grafts had attached well, standard wound care was
continued using a nonadhesive dressing (Atrauman) and a
multilayer compression bandage (Rosidal K), when possi-
ble, until complete healing.
In both treatment groups, only toilet and basic hy-
giene mobility was permitted during the wound bed
preparation and transplantation stage. After complete
wound healing, community-grade elastic support stock-
ings class 2 (Mediven 550, Medi Nederland B V, Breda,
The Netherlands; or Eurostar, Varodem, Horn, The Neth-
erlands) or 3 (Eurostar, Varodem, Horn, The Netherlands)
were prescribed, depending on the cause of the ulcer.
Evaluation criteria. Because masking the interven-
tions was not possible, patients were reviewed clinically by
the same independent research physician and consultant
dermatologist twice a week until wound closure. Thereaf-
ter, the same research physician prospectively monitored the
patients at 3, 6, and 12 months after discharge. All participat-
ing clinicians completed standardized case record forms dur-
ing their control visits, treatments, and follow-ups.
Two time spans in wound healing were distinguished:
(1) the wound bed preparation, and (2) the time to com-
plete healing. The stage for wound bed preparation was
defined as the time between surgical débridement and
application of the punch skin grafts. The time to complete
healing, being the primary end point, was defined as the
period between surgical débridement and 100% epithelial-
ization (wound closure). Patients were only discharged
after complete healing; therefore, length of hospital stay
equalled total healing time. Secondary end points included
(1) duration of the wound bed preparation, (2) percentage
of ulcer recurrences 1 year after discharge, defined as an
epithelial breakdown anywhere along or within the index
leg ulcer region, and (3) skin-graft survival, defined as the
percentage of successfully adhered skin grafts after 4 days of
complete bed rest and local therapy. Furthermore, we
compared between both experimental groups the QOL,
pain scores, the total time needed for wound care until
complete wound closure, and the costs per ulcer.
Quality of life and pain scores. Quality of life was
measured at baseline and once a week during hospitaliza-
tion using the EuroQol Derived Single Index (EQ-DSI).
This index is a generic questionnaire consisting of five
dimensions: mobility, self-care, usual activities, pain and
discomfort, and anxiety and depression.24 Scoring of these
parameters can be transformed into a single index of health
status, with the highest score reflecting the best possible
health status. During dressing changes, pain scores were
derived using the Short Form-McGill Pain Questionnaire
(SF-MPQ) and the Present Pain Intensity (PPI) score as
adjectival pain scale, as previously reported.25 The SF-MPQ is
designed to provide quantitative measures of clinical pain.
It consists of 15 descriptors of 11 sensory and four affectiveitems, with a maximum response of three for each item
(maximum possible sensory and affective score is 33 and
12, respectively). Pain intensity using the PPI score was
recorded on a scale from 1 to 5, with 1, mild; 2, discom-
forting; 3, distressing; 4, horrible; and 5, excruciating.
Time consumption. The total time needed for wound
care until total wound closure was based on empirical time
registration by the attending dermatologist and the nurse
who performed wound care. Both time spans were calcu-
lated in minutes.
Cost analysis. The total costs related to wound care
for each ulcer included the salary for personnel and the
material costs for wound care procedures until the moment
of complete healing. Personnel costs for each procedure
were based on empirical time registrations by the derma-
tologist and nurse who performed the wound care. Because
we chose to keep patients hospitalized until complete
healing was achieved, in contrast to normal clinical prac-
tice, we did not incorporate admission costs in the
budget. Costs related to materials were based on actual
cost prices as calculated by the financial department of
the University Hospital Maastricht. The costs of both
treatment modalities were calculated in dollars ($) for
each ulcer.
Statistical analysis. Data from a retrospective study
showed that the mean  SD duration of the 90% wound
closure period was 50  12 days in standard would care vs
31 7 days in V.A.C.17 To detect a minimal difference of
7 days in preparation time with a power of 95% (  5%),
the number of patients required in each treatment-group
was 30, as derived from sample-size calculations.
Results were analyzed on an intention-to-treat basis.26
Time to complete healing (Fig 1), duration of wound bed
preparation (Fig 2), and recurrence rates (Fig 3) were
compared using the Kaplan-Meier survival analysis.27 The
log-rank test was used to test for statistically significant
differences between the groups.27 To adjust for small im-
balances in the baseline distribution of relevant prognostic
factors (Table I) to wound healing, multivariate analysis
was performed using Cox’s proportional hazards model
(Table II).13,28,29 The regression coefficient expresses the
independent contribution of potential determinants to du-
ration of cleaning and wound healing. Hazard ratios (HR)
and their 95% confidence intervals (CI) are presented. P 
.05 was considered to be statistically significant.
Percentages were compared by the 2 test, and contin-
uous variables were compared using the independent sam-
ples t test for normally distributed variables and the
two-independent sample test for non-normally distributed
variables. The paired t test was used to compare QOL scores
before treatment and at the end of follow-up. All data were
analyzed using the SPSS 11.0 software package (SPSS Inc,
Chicago, Ill).
RESULTS
Recruitment. From May 2001 to May 2003, 71 pa-
tients with 85 CLUs were hospitalized and screened for
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included because they were not interested in participating.
Protocol violations. Four randomized patients (n 4
ulcers), two in the V.A.C. group and two in the control group,
did not complete the protocol due to reasons mentioned in
Fig 4. In addition, one patient switched from conventional to
V.A.C. therapy after 8 weeks due to an unsatisfactory thera-
peutic outcome. Finally, during analysis it became apparent
that two patients were falsely included because they had pe-
ripheral arterial disease. Still, the therapeutic outcome in these
Enrollment
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Fig 1. Time to complete healing (days) in the vacuu
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controls were lost due to reasons outlined in Fig 1.
Patient and ulcer characteristics. Among the 60 pa-
tients, 51 had one ulcer, six had two ulcers, and three had
three ulcers (n  72 ulcers). All patients gave informed
consent for inclusion in the study and were randomly
allocated between the two treatment arms (Fig 4).
Patient and ulcer characteristics of both groups are
shown in Table I. Although the median ulcer surface area
was larger in the control group, no statistical differences
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clinical characteristics.13,28,29
Effectiveness of V.A.C. vs conventional wound
care. Kaplan-Meier survival analysis showed that the time
to complete healing was reduced in the V.A.C. group (P
.0001). The median total healing time was 29 days (95%
CI, 25.5 to 32.5) in the V.A.C. group vs 45 days (95% CI,
36.2 to 53.8) in the control group. Ninety percent of the
ulcers treated with V.A.C. healed within 43 days. At that
point, only 48% of all ulcers in the control group had healed
(Fig 1). As patients were only discharged after complete
healing, length of hospital stay equalled total healing time.
Only one ulcer failed to heal in both the control and V.A.C.
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Fig 2. Wound bed preparation time (days) in the vacuum-assisted
closure (V.A.C.) group compared with standard wound care.
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Fig 3. Recurrence rate (months) in the vacuum-assisted closure
(V.A.C.) group compared with standard wound care.treated groups, respectively.V.A.C. therapy resulted in a significantly shorter wound
bed preparation time (P  .005). The median preparation
time was 7 days (95% CI, 5.7 to 8.3) in the V.A.C. group vs 17
days in the control group (95% CI, 10 to 24). Moreover, 90%
of the ulcers treated with V.A.C. could be cleaned within 14
days. By contrast, only 37% of the ulcers in the control
group could be cleaned within this time span (Fig 2).
Cox multivariate regression analysis (Table II) showed
that that treatment by V.A.C. was still associated with
significant faster time to complete healing (HR 3.2; 95%
CI, 1.7 to 6.2) and preparation time (HR  2.4; 95% CI,
1.2 to 4.7) independently of small imbalances in prognostic
factors (eg, the ulcer surface area) to wound healing be-
tween both study groups.
Secondary outcomes. Kaplan-Meier survival analysis
(Fig 3, Table III) showed a median recurrence rate at
month 4 (95% CI, 0.7 to 7.4) after the V.A.C. therapy vs
month 2 (95% CI, 0.5 to 3.6) in the control group (P 
.47). After 1-year follow-up (Table III), 52% (n  12) of all
healed V.A.C. ulcers relapsed compared with 42% (n 10)
in the control group (P  .47). All differences were not
statistically significant.
The median percentage of successful skin grafts
(Table III) differed significantly (P  .011) between the
V.A.C. and control groups, with 83% 14% vs 70% 31%.
The total nursing time consumption (Table III) was
significantly longer during standard wound care (386 
178 minutes) than during V.A.C. therapy (232  267
minutes; P  .001). There were no significant differences
(P  .937) between the V.A.C. and control groups with
respect to time consumption for medical attention through
the physician (177  76 minutes vs 181  91 minutes).
Quality of life. During the hospitalization period, 56
ulcers healed. Changes in QOL and in pain scores are
presented in Table IV. The study groups showed significant
increases in QOL at the end of therapy. During the first
week, the QOL score was significantly lower in the V.A.C.
group (P  .031); however, this difference had already
disappeared in the second week, and during follow-up, life
quality was similar in both groups.
With respect to pain scores, both groups showed a
significant decrease at the end of follow-up, too. Compar-
ison of pain scores revealed that the scores were initially
similar during the first weeks of treatment. From week 5
onwards, however, PPI scores were significantly lower in
the V.A.C. group.
Cost analysis. We have listed wound care costs in
Table V. Costs for personnel were calculated on the basis of
average fees for medical and nursing personnel adjusted for
the clocked time spent by medical doctors and nurses with
the patients. The total wound care costs for a hospitalized
CLU were 25% to 30% lower for V.A.C. than for standard
wound care (Mann-WhitneyU test, P .001). Because we
chose to keep patients hospitalized until complete heal-
ing was achieved, in contrast to normal clinical practice,
we did not incorporate admission costs in the cost anal-
ysis. Considering that length of hospital stay was signif-
icantly longer for patients with standard wound care, the
ythem
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greater.
Complications. The complication rate was higher in
the V.A.C. group (40%) compared with the control group
(23%), but the difference was not statistically significant
(P  .17). Table VI summarizes all adverse events.
DISCUSSION
Despite the development of modern diagnostic tools
Table I. Demographic and clinical characteristics
Male
Female
Age
Median ulcer chronicity at inclusion (months)
Median ulcer surface (length  width  cm2)
Smoking
Diabetes mellitus type II
Immobility
Hypertension
No ulcer history
Ulcer environment (0-4)‡
Infection signs (Pseudomonas aeruginosa)
Median ankle-brachial index (%)
Medication use
Antibiotics
Nonselective -blockers
ACE inhibitors
Selective 1-blockers
Anticlotting therapy
Ca2	 antagonists
Ulcer type
Venous origin
CEAsP
CEApP
CEAdP
Combined venous/arterial origin
Arteriolosclerotic origin
SWC, Standard wound care; ACE, angiotensin-converting enzyme inhibito
*Data are median (minimum-maximum) or number and (%) unless otherw
†Mann Whitney U test; 2 or Fisher exact as appropriate.
‡Ulcer environment (surrounding skin symptoms like petechiae, eczema, er
Table II. Hazard ratios with 95% confidence intervals for
wound healing
Wound bed preparation dur
Variable HR 95% CI
Ulcer area (cm2) 0.56 0.29-1.09
Smoking 0.5 0.20-1.21
Infection signs 0.45 0.21-1.21
Ulcer history 1.08 0.61-1.91
Therapy 2.4 1.19-4.71
ACE inhibitors 1.9 0.57-2.07
Anticlotting therapy 1.03 0.53-2.01
HR, Hazard ratio; CI, confidence interval; ACE, angiotensin-converting en
*Significant difference P  .05.and remarkable therapeutic improvement, many CLUs donot heal satisfactorily in an outpatient clinic within a certain
time period.2-5,6-10,30 Furthermore, current treatment mo-
dalities are time consuming and expensive.2 In this study,
we used a prospective and comparative study model to
evaluate the efficacy of V.A.C. treatment in recalcitrant
CLUs treated in an inpatient facility compared with current
standard therapeutic regimens. Our study shows that
V.A.C. therapy results in a significant reduction of wound
preparation time and the time to complete healing com-
Treatment
WC
30)*
V.A.C.
(n  30)* P
23) 7 (23) NS
77) 23 (77)
45-83) 74 (53-81) NS†
6-12) 8 (6-24) NS†
3-250) 33 (2-150) NS†
30) 6 (21) NS
17) 5 (17) NS
43) 12 (41) NS
40) 13 (45) NS
47) 12 (40) NS
0-4) 2 (0-4) NS
20) 8 (28) NS
59-130) 100 (59-100) NS†
NS
3) 1 (4)
17) 4 (15)
30) 6 (23)
17) 4 (15)
23) 10 (39)
13) 1 (4)
43) 13 (43) NS
54) 9 (69)
46) 3 (23)
1 (8)
13) 4 (13) NS
43) 13 (43) NS
cified.
a, and/or maceration).
rminants of duration of wound-bed preparation and
Wound healing duration
P HR 95% CI P
0.09 0.5 0.25-1.01 0.058
0.3 0.4 0.16-0.98 0.056
0.12 0.99 0.46-2.16 0.98
0.79 0.93 0.50-1.71 0.8
.01* 3.22 1.66-6.21 .000*
0.8 0.95 0.49-1.82 0.88
0.92 0.69 0.35-1.38 0.3
inhibitor.S
(n 
7 (
23 (
72 (
7 (
43 (
9 (
5 (
13 (
12 (
14 (
2 (
6 (
100 (
1 (
5 (
9 (
5 (
7 (
4 (
13 (
7 (
6 (
0
4 (
13 (
rs.
ise spedete
ation
zymepared with common treatment modalities. Because ambu-
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might be offered on an outpatient basis. Providing that
patients adhere strictly to the treatment protocol and
trained wound care nurses are employed, the same efficacy
may be reached in an outpatient setting.
Mouës et al31 randomized patients with acute traumatic
or infected wounds, pressure ulcers, and other chronic leg
ulcers to V.A.C. vs standard wound care. They did not find
any difference in wound bed preparation time; however, they
did observe a significant reduction in wound area surface by
V.A.C., implying a positive effect of V.A.C. on wound heal-
ing. Their failure to observe decreased wound bed preparation
time may be related to inclusion of patients with acute infected
or traumatic wounds.
For practical reasons, we subdivided the time to com-
plete healing and distinguished the preparation phase and
the overall complete healing time. Apparently, the greatest
benefit of V.A.C. in our study is reflected by a reduced
median preparation time of 58% during the first time period
(Fig 2). The overall complete healing time was reduced by
35% (Fig 1). These data demonstrate that V.A.C. is an
extremely valuable tool in wound bed preparation.
With this randomized clinical trial, we sought to assess the
effect of V.A.C. therapy on wound healing in patients with
recalcitrant CLU irrespective of underlying etiology. This
approach may have increased the external validity of our
findings, but it imposes some limitations on the interpretation
of the results, especially since the number of patients is insuf-
ficient to perform subgroup analyses for each type of CLU
individually. Nevertheless, keeping in mind this limitation,
V.A.C. therapy resulted in a decreased wound preparation
time and total wound healing time within each CLU group
(ie, venous, arteriolosclerotic, or combined venous/arterial).
For the venous and arteriolosclerotic ulcers, but not for the
combined venous/arterial ulcers, this difference reached sta-
tistical significance (data not shown).
In the past, two main factors have been documented to
0,00 2,00 4,00 6,00 8,00 10,00 12,00 14,00
Recurrence rate (months)
0,0
0,2
0,4
0,6
0,8
1,0
O
n
e 
M
in
u
s 
C
u
m
 S
u
rv
iv
al
Therapy
Control group
V.A.C.® group
Fig 4. Trial profile. V.A.C., Vacuum-assisted closure.exert an important influence on wound healing. First, it hasbeen shown that chronic wound exudate may disturb nor-
mal wound healing because these fluids contain lower
amounts of growth-promoting cytokines, persistent ele-
vated inflammatory cytokines, and proteolytic enzymes.3,14
Second, the considerable effects of mechanical forces on
wound shape and tissue growth have been reported.32
V.A.C. therapy has been repeatedly used successfully to
positively influence both factors by removing excess inter-
stitial fluid and transmitting mechanical forces to the sur-
rounding tissue.15,16,33
In support of this notion, a recent report indicated that
reduced levels of matrix metalloproteinases 1, 2, and 13 dur-
ing V.A.C. presumably result in reduced collagen break-
down.34 Further, active reduction of excessive wound fluid
also results in decompression of small blood vessels, restores
microcirculation, and increases oxygen and nutrient delivery
to the wound. All these factors notably improve the rate of
granulation tissue formation.16,33 The positive influences
of mechanical forces on the growth of tissues, especially in
stimulating cell migration and mitosis during V.A.C., are
also documented.16,33,35 Further, an occlusive environ-
ment, as created by adhesive transparent dressings during
V.A.C., markedly supports maintenance of a controlled,
moist wound environment and reduces the chance of infec-
tion.16,33,35 All of these factors have been shown to result
in improved wound healing.
A critical aspect in the survival of a skin graft is an adequate
contact with the granulated wound bed. With conventional
treatment using compression bandages, the survival rates of
skin grafts is usually much lower owing to excessively exuda-
tive wound bed surfaces and surfaces subjected to motion.23
These difficulties can be overcome though by application of
V.A.C., as demonstrated by Scherer et al23 and confirmed in
our study (Table III) by the higher percentage of adhered skin
grafts (80% vs 70%, P .011).
One of the major problems in leg ulcer treatment is
the high frequency of relapses.13 Interestingly, recur-
rence rates in CLUs after treatment with V.A.C. therapy
compared with standard wound care modalities have not
Table III. Secondary outcomes
Conventional
treatment V.A.C. P
Recurrence percentage (n) 42% (10) 52% (12) .405*
Median recurrence moment
(month) 2nd 4th .47†
Median percentage skin graft
survival (SD)‡ 70% (31) 83% (14) .011§
Median wound care time (SD)
Nurse* 330 (178) 232 (267) .001§
Physician 181 (91) 177 (76) .937§
V.A.C., Vacuum-assisted closure.
*2 test.
†Log-rank test.
‡Significant difference P  .05.
§Mann-Whitney U test.been reported to date, to the best of our knowledge.
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daily practice if V.A.C. revealed lower recurrence rates
than standard wound care regimens. We observed 12
recurrences (52%) in the V.A.C. group and 10 relapses
(42%) after standard wound care at the 12-month fol-
low-up (Table III). Although this difference was not
significant, larger study cohorts are certainly needed to
determine a putative positive effect of V.A.C. with re-
spect to ulcer recurrence rates.
Recently, socioeconomic and QOL studies in pa-
tients with CLUs revealed the broad impact of this
long-neglected health care problem on everyday rou-
tine.36 Persoon et al36 convincingly demonstrated a
strong correlation between the amount of time spent on
ulcer care, feelings of anger, and the QOL of patients. In
Table IV. Mean (SD) quality-of-life scores in the V.A.C.
Week 0 1 2 3
EQ-5D
V.A.C. 40 (13) 39 (16)* 47 (15) 62 (13)
Controls 45 (19) 49 (19)* 51 (18) 60 (16)
SF-MPQ
V.A.C. 9 (4) 10 (5) 6 (3) 5 (3)
Controls 10 (3) 10 (4) 7 (4) 6 (3)
PPI
V.A.C. 2.5 (1)* 3 (1) 1.9 (1) 1.4 (1)
Controls 3.1 (1)* 3.2 (1) 2.6 (1) 1.8 (1)
V.A.C., Vacuum-assisted closure; EQ-5D, EuroQol  5 Dimensions index;
*Mann Whitney U test, P  .05.
Table V. Average costs of treatment
Conventional
treatment (n  30)
V.A.C.
(n  30) P
V.A.C. related products ($) 0 847
Bandages and dressings ($) 4770 2391
Personnel costs ($) 508 583
Nurse costs ($) 175 124
Total ($) 5452 3881 .001*
*Mann-Whitney U test, P  .05.
Table VI. Adverse events
Conventional
treatment (n  30)
V.A.C.
(n  30)
Erysipelas 0 1
Pain 1 3
Cutaneous damage secondary
to therapy* 2 7
Wound infection 1 0
Postoperative bleeding at
donor site 2 0
Nonhealing ulcer 1 1*
V.A.C., Vacuum-assisted closure.
*Mann Whitney U test, P  .05.our study, the overall subjective QOL measured by theEQ-DSI and pain scores improved significantly in both
groups within 8 weeks but did not differ significantly.
Still, the improvement in QOL was achieved more rap-
idly in the V.A.C. group despite an initial decrease
during the first week of treatment (Table IV). This may
be explained by an accelerated wound preparation phase
with V.A.C. A possible explanation for the initial de-
crease during V.A.C. treatment might be that patients
experienced the necessity of strict bed rest as a factor
negatively influencing QOL.
Wound care costs for the treatment of CLUs follow-
ing standard protocols were significantly higher than
those in the V.A.C. group. The biggest part of this cost
difference was caused by higher personnel costs and
longer hospitalization time due to slower wound healing
in the control group. We are aware that this wound care
time might not represent the real situation, because in
daily practice, most patients with leg ulcers will be dis-
charged once the ulcers are almost closed.
Several recently developed products have shown fa-
vorable results in the treatment of chronic (venous) leg
ulcers compared with compression therapy, including
bilayered bioengineered skin substitute,37 cultured allo-
geneic human skin equivalent,10 and porcine small intes-
tine submucosa.10 Because V.A.C. therapy has a strong
beneficial effect on wound bed preparation, combination
with one of these products, after a well granulating
wound bed has been created with V.A.C. therapy, may
improve treatment of recalcitrant CLU.
CONCLUSION
This prospective randomized controlled trial demon-
strated that V.A.C. therapy leads to a significant im-
provement in wound management of recalcitrant CLUs.
Therefore, V.A.C. therapy should be considered as the
treatment of choice for CLUs. Future prospective studies
with inclusion of more patients will be needed though to
determine the effects of V.A.C. with respect to ulcer recur-
rence rates.38
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